ArticleISRN pharmacology2013
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.
Article in ISRN pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.The pharmacogenomics journal · 2021Pooled it
- Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.Clinical pharmacology and therapeutics · 2017Pooled it
- Population frequencies of thiopurine-related pharmacogenes in healthy individuals from Kosovo.Human genome variation · 2026Article
- Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions.European journal of human genetics : EJHG · 2026Review
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- Toward Integration of Pharmacogenomic Tests into Daily Clinical Practice: A General Survey for Polish Healthcare Workers.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study.Journal of clinical medicine · 2022Article
- Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy.International journal of health economics and management · 2021Article
- Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice.Frontiers in pharmacology · 2021Review
- Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.Pharmaceutics · 2020Review
- Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Article
- Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.Frontiers in pharmacology · 2019Review
- Medication Exposure Patterns in Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids.Qualitative report (Online) · 2018Article
- The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Pharmaceutical research · 2017Review
- Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.Pharmacogenetics and genomics · 2017Article
- Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.The pharmacogenomics journal · 2017Article
- Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
- A physiome interoperability roadmap for personalized drug development.Interface focus · 2016Article
- Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.American family physician · 2015Article
- Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Clinical pharmacology and therapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mapping of the human genome and subsequent advancements in genetic technology had provided clinicians and scientists an understanding of the genetic basis of altered drug pharmacokinetics and pharmacodynamics, as well as some examples of applying genomic data in clinical practice. This has raised the public expectation that predicting patients' responses to drug therapy is now possible in every therapeutic area, and personalized drug therapy would come sooner than later. However, debate continues among most stakeholders involved in drug development and clinical decision-making on whether pharmacogenomic biomarkers should be used in patient assessment, as well as when and in whom to use the biomarker-based diagnostic tests. Currently, most would agree that achieving the goal of personalized therapy remains years, if not decades, away. Realistic application of genomic findings and technologies in clinical practice and drug development require addressing multiple logistics and challenges that go beyond discovery of gene variants and/or completion of prospective controlled clinical trials. The goal of personalized medicine can only be achieved when all stakeholders in the field work together, with willingness to accept occasional paradigm change in their current approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.